TG Therapeutics
TGTX
63.34
-1.54
-2.37%
TG Therapeutics
US · TGTX
#1638 by market cap
Listed 1970
63.34
-1.54
-2.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About TG Therapeutics
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
- Founded
- 1993
- CEO
- Mr. Michael S. Weiss
- Employees
- 399
- Headquarters
- Morrisville, North Carolina, United States of America
- Fiscal year end
- 12-31
- Website
- tgtherapeutics.com
Company profile
- Exchange
- US
- Symbol
- TGTX
- Market-cap rank
- #1638
- Listing date
- 1970-01-01
- Market cap
- 9.57B
- Float cap
- 9.16B
- Shares out
- 151.15M
- Float shares
- 144.54M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.
TG Therapeutics discussion 0 comments